stockrowT2 Biosystems, Inc.
TTOO Healthcare Diagnostics & Research
T2 Biosystems, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $7.2 million, down 67.8% from fiscal 2022.
Follow TTOO
Alert me
T2 Biosystems, Inc. (TTOO) EV/Sales
As of 5 November 2026, T2 Biosystems, Inc. (TTOO) trades at a EV/Sales of 6.3×. Over the past ten years it has ranged from −0.2× (April 2020) to 760× (April 2015); the current reading is higher than 38% of that period. That is above the Diagnostics & Research industry median of 5.2× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 6.7× | 216.99% |
| FY2022 | 2.1× | (38.82%) |
| FY2021 | 3.5× | (58.96%) |
| FY2020 | 8.5× | 60.33% |
| FY2019 | 5.3× | (22.45%) |
| FY2018 | 6.8× | (68.72%) |
| FY2017 | 21.8× | (13.48%) |
| FY2016 | 25.2× | (60.14%) |
| FY2015 | 63.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2024 | 10.8× | (36.15%) |
| Jun 2024 | 17.0× | 106.32% |
| Mar 2024 | 8.2× | 22.01% |
| Dec 2023 | 6.7× | (42.77%) |
| 35 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| DMTKQ DermTech, Inc. compare | −2.5× |
| ISPC iSpecimen Inc. compare | −1.5× |
| BIAF bioAffinity Technologies, Inc. compare | −0.2× |
| XWEL XWELL, Inc. compare | −0.1× |
| ADVB Advanced Biomed Inc. compare | n/m |
| MDXH MDxHealth SA compare | 0.8× |
| AWHL Aspira Women's Health Inc. compare | 1.2× |
| NDRA ENDRA Life Sciences Inc. compare | 1.9× |
| TTOO T2 Biosystems, Inc. | 6.3× |
| Diagnostics & Research industry median | 5.2× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)